ePrints

Compliance and satisfaction with switchig from an immediate-release to sustained-release formulation of valproate in people with epilepsy

Lookup NU author(s): Julie Doughty

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Objective. The goal of our work was to assess compliance and patient satisfaction with switching from sodium valproate to Depakine Chrono in patients with epilepsy. Methods. Clinical, demographic, and behavioral details assessing compliance and satisfaction were collected using self-completion questionnaires at the time of inclusion in the study and 3 months after the inclusion day. Results. Data were collected from 2031 respondents from eight European countries. There were significant differences between time 1 and time 2 of the study in seizure frequency, reported side effects, compliance, and patient satisfaction. Conclusion. Findings suggest that switching from sodium valproate to Depakine Chrono results in an increase in seizure-free rates, a reduction in reported side effects, an improvement in the level of compliance, and a modest improvement in patient satisfaction. © 2003 Elsevier Inc. All rights reserved.

Publication metadata

Author(s): Doughty J, Baker GA, Jacoby A, Lavaud V

Publication type: Article

Publication status: Published

Journal: Epilepsy and Behavior

Year: 2003

Volume: 4

Issue: 6

Pages: 710-716

ISSN (print): 1525-5050

ISSN (electronic): 1525-5069

Publisher: Academic Press

URL: http://dx.doi.org/10.1016/j.yebeh.2003.08.013

DOI: 10.1016/j.yebeh.2003.08.013

PubMed id: 14698705

Altmetrics

Share